Abstract
Objective
To determine whether systemic antifungal prophylaxis decreases infectious morbidity and mortality in nonneutropenic, critically ill, trauma and surgical intensive care unit (ICU) adult patients.
Design
Systematic review and meta-analysis of randomized clinical trials. We used a fixed effect model, with risk ratio (RR) and 95% confidence intervals (CI).
Participants
Patients admitted to ICU after surgery or trauma, with multiple risk factors for fungal infections.
Interventions
Nine studies (seven double blind) with a total of 1,226 patients compared ketoconazole (three) or fluconazole (six) to placebo (eight) or no treatment (one).
Results
Prophylaxis with azole was associated with reduced rates of candidemia (RR 0.30, 95% CI 0.10–0.82), mortality attributable to Candida infection (RR 0.25, 95% CI 0.08–0.80), and overall mortality (RR 0.60, 95% CI 0.45–0.81). Time to event analysis showed a significantly lower probability of fungal infections in treated patients. There was no evidence of statistical heterogeneity between studies, and publication bias assessment gave a negative results. There was, however, wide variability in the definition and reporting of some relevant clinical outcomes (e.g., confirmed or suspected infections, colonization) and pooling of these outcome measures was not feasible.
Conclusions
Prophylaxis of candidal infection among critically ill ICU patients has beneficial effect on certain outcome measures, but additional data from well designed clinical trials and long-term epidemiological observations are needed to provide firm recommendations for the selection of subgroups of patients who would most benefit from prophylaxis and to determine the effect of prophylaxis on fungal resistance patterns.
Similar content being viewed by others
References
Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP; National Epidemiology of Mycoses Survey (NEMIS) Study Group (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33:177–186
Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Tauber MG, Pittet D; Fungal Infection Network of Switzerland, Fungal Infection Network of Switzerland (2004) Epidemiology of candidaemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis 38:311–320
Sobel JD, Rex JH (2001) Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis 33:187–190
Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274:639–644
Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R; ECMM Working Group on Candidaemia (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23:317–322
Petri MG, Konig J, Moecke HP, Gramm HJ, Barkow H, Kujath P, Dennhart R, Schafer H, Meyer N, Kalmar P, Thulig P, Muller J, Lode H (1997) Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med 23:317–325
Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards JE Jr, Jarvis W, Dawson J, Wenzel RP (1999) National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 29:253–258
Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S (2002) Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 94:3230–3246
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751
Rex JH, Sobel JD (2001) Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 32:1191–1200
British Society for Antimicrobial Chemotherapy Working Party (1994) Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 20:522–528
Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE (2000) Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30:662–678
Lipsett PA (2004) Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations. Clin Infect Dis 39 [Suppl 4]:S193–S199
Calandra T, Marchetti O (2002) Antifungal prophylaxis for intensive care unit patients: let’s fine tune it. Intensive Care Med 28:1698–1700
Calandra T, Marchetti O (2004) Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 39 [Suppl 4]:S185–S192
Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, Hiramatsu Y, Nitenberg G, Nystrom PO, Pittet D, Rogers T, Sandven P, Sganga G, Schaller MD, Solomkin J (1998) Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 24:206–216
Cruciani M, Mengoli C, de Lalla F (2004) Meta-analysis of antifungal prophylaxis in trauma and surgical intensive care patients (abstract K-1433). Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 30 October 30–2 November, Washington
Eggimann P, Garbino J, Pittet D (2003) Management of Candida species infections in critically ill patients. Lancet Infect Dis 3:772–785
Slotman GJ, Burchard KW (1987) Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg. Arch Surg 122:147–151
Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L (1994) Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 36:20–25
Eggimann P, Francioli P, Bille, Schneider R, Wu MM, Chapuis G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, Glauser MP, Calandra T (1999) Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 27:1066–1072
Ables AZ, Blumer NA, Valanis GT, Godenick MT, Kajdasz DK, Palesch YY (2000) Fluconazole prophylaxis of severe Candida infection in trauma and post-surgical patients: a prospective, double-blind randomized, placebo-controlled trail. Infect Dis Clin Pract 9:169–175
Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA (2001) Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 233:542–548
Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D (2002) Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 28:1708–1717
Jacobs S, Price Evans DA, Tariq M, Al Omar NF (2003) Fluconazole improves survival in septic shock: a randomized double blind prospective study. Crit Care Med 31:1938–1946
Slotman GJ, Burchard KW, D’Arezzo A, Gann DS (1988) Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma 28:648–654
Sandven P, Qvist H, Skovlund E, Giercksky KE; NORGAS Group, the Norwegian Yeast Study Group (2002) Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 30:541–547
He YM, Lv XS, Ai ZL, Liu ZS, Qian Q, Sun Q, Chen JW, Lei DX, Jiang CQ, Yuan YF (2003) Prevention and therapy of fungal infection in severe acute pancreatitis: a prospective clinical study. World J Gastroenterol 9:2619–2621
Yu M, Tomasa G (1993) A double-blind, prospective, randomized trial of ketoconazole, a tromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 21:1635–1642
Havliceck K, Motycka H, Sakra L, Mencl K, Ninger V, Safusova L (2002) Preemptive antimycotic therapy in critically ill patients. Rozhl Chir 2003 82:67–71
Guan J, Yang XY, Zhao L (2004) Preventive effect and clinical significance of garlicin injection on mechanical ventilator-associated low respiratory tract deep-seated fungal infection. Zhongguo Zhong Xi Yi Jie He Za Zhi 24:505–507
Swoboda SM, Merz WG, Lipsett PA (2003) Candidaemia: the impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect 4:345–354
Kappe R, Streitzig S, Bohrer H (2001) Retrospective analysis of fluconazole efficacy in Candida-colonized, non-neutropenic, surgical patients in long-term intensive care. Dtsch Med Wochenschr 126:905–908
Rocco TR, Reinert SE, Simms HH (2000) Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg 135:160–165
Vinsant GO, Todd J, Fallon W (1993) Reduction of Candida infections in high-risk trauma patient. Poster presented at the American College of Surgeons Clinical Congress, 11–14 October San Francisco
Magill SS, Puthanakit T, Swoboda SM, Carson KA, Salvatori R, Lipsett PA, Hendrix CW (2004) Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients. Antimicrob Agents Chemother 48:2471–2476
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Laupacis A, Sackett DL, Roberts RS (1988) An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318:1728–1733
Messori A, Rampazzo R (1993) Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer. Comput Methods Programs Biomed 40:261–267
Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B 34:187–220
Berkey CS, Hoaglin DC, Mosteller F, Colditz GA (1995) A random-effects regression model for meta-analysis. Stat Med 14:395–411
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1011
Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129
Higgins J, Thompson S, Deeks J, Altman D (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
Ascioglu S, de Pauw BE, Donnelly JP, Collette L (2001) Reliability of clinical research on invasive fungal infections: a systematic review of the literature. Med Mycol 39:35–40
Gotzsche PC (2000) Why we need a broad perspective on meta-analysis. It may be crucially important for patients. BMJ 321:585–586
Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751–758
Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Hammond JM, Hendrix CW (2000) The diagnostic value of fungal surveillance cultures in critically ill patients. Surg Infect 1:273–281
Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1989) Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 149:2349–2353
Lipman J, Saadia R (1997) Fungal infections in critically ill patients. BMJ 315:266–267
Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, Boillot A (2004) Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 32:2443–2449
Andrews P, Azoulay E, Antonelli M, Brochard L, Brun-Buisson C, Dobb G, Fagon JY, Gerlach H, Groeneveld J, Mancebo J, Metnitz P, Nava S, Pugin J, Pinsky M, Radermacher P, Richard C, Tasker R, Vallet B (2005) Year in review in intensive care medicine, 2004. I. Respiratory failure, infection, and sepsis. Intensive Care Med 31:28–40
Pelz RK, Lipsett PA, Swoboda SM, Merz W, Rinaldi MG, Hendrix CW (2002) Enteral fluconazole is well absorbed in critically ill surgical patients. Surgery 131:534–540
Berrouane YF, Herwaldt LA, Pfaller MA (1999) Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 37:531–537
Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL (1996) The changing face of candidaemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100:617–623
Gleason TG, May AK, Caparelli D, Farr BM, Sawyer RG (1997) Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 132:1197–1201
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
Cruciani, M., de Lalla, F. & Mengoli, C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 31, 1479–1487 (2005). https://doi.org/10.1007/s00134-005-2794-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-005-2794-y